Endosialin: From Vascular Target to Biomarker for Human Sarcomas

• Hodgson DR , WhittakerRD, HerathA, AmakyeD, ClackG: Biomarkers in oncology drug development.Mol. Oncol.3, 24–32 (2009).
   PubMed Web of Science ®Google Scholar
• Atkinson AJ , ColburnWA, DeGruttolaVGet al. : Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.Clin. Pharmacol. Ther.69, 89–95 (2001).
   PubMed Web of Science ®Google Scholar
• Dhani N , SiuLL: Clinical trials and biomarker development with molecularly targeted agents and radiotherapy.Cancer Metastasis Rev.27, 339–349 (2008).
   PubMed Web of Science ®Google Scholar
• Kelloff GJ , BastRC, CoffeyDSet al. : Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment.Clin. Cancer Res.10, 3881–3884 (2004).
   PubMed Web of Science ®Google Scholar
• McShane LM , HunsbergerS, AdjeiAA: Effective incorporation of biomarkers into Phase II trials.Clin. Cancer Res.15(6), 1898–1905 (2009).
   PubMed Web of Science ®Google Scholar
• Williams SA , SinghP, IsaacsJT, DenmeadeSR: Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?Prostate67(3), 312–329 (2006).
   Web of Science ®Google Scholar
• Gronlund B , HogdallC, HildenJ, EngelholmSA, HogdallEVS, HansenHH: Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?J. Clin. Oncol.22, 4051–4058 (2004).
   PubMed Web of Science ®Google Scholar
• Elkin EB , WeinsteinMC, WinerEP, KuntzKM, SchnittSJ, WeeksJC: HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effective analysis.J. Clin. Oncol.22(5), 854–863 (2004).
   PubMed Web of Science ®Google Scholar
• Dowsett M , DumbierAK: Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.Clin. Cancer Res.14(24), 8019–8026 (2008).
   PubMed Web of Science ®Google Scholar
• Alitalo K , tammelaT, PetrovaTV: Lymphangiogenesis in development and human disease.Nature438, 946–953 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrara N , KerbelRS: Angiogenesis as a therapeutic target.Nature438, 967–974 (2005).
   PubMed Web of Science ®Google Scholar
• Hicklin DJ , EllisLM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.J. Clin. Oncol.23(5), 1011–1027 (2005).
   PubMed Web of Science ®Google Scholar
• Rettig W , Garin-ChesaP, HealeyJH, SuSL, JaffeEA, OldLJ: Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer.PNAS89, 10832–10836 (1992).
   PubMed Web of Science ®Google Scholar
• Christian S , AhornH, KoehlerAet al. : Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium.J. Biol. Chem.276(10), 7408–7414 (2001).
   PubMed Web of Science ®Google Scholar
• Conway EM , Van de WouwerM, PollefeytSet al.: The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor κB and mitogen-activated protein kinase pathways.J. Exp. Med.196(5), 565–577 (2002).
   PubMed Web of Science ®Google Scholar
• Greenlee MC , SullivanSA, BohlsonSS: CD93 and related family members: their role in innate immunity.Curr. Drug Targets9(20), 130–138 (2008).
   PubMedGoogle Scholar
• Van de Wouwer M , ConwayEM: Novel functions of thrombomodulin in inflammation.Crit. Care Med.32(5), S254–S261 (2004).
   PubMed Web of Science ®Google Scholar
• Hanly AM , WinterDC. The role of thrombomodulin in malignancy. Semin. Thromb. Hemost.33, 673–679 (2007).
   PubMed Web of Science ®Google Scholar
• Lager DJ , CallaghanEJ, WorthSF, RaifeTJ, LentzSR: Cellular localization of thrombomodulin in human epithelial squamous malignancies.Am. J. Pathol.146(4), 933–943 (1995).
   PubMed Web of Science ®Google Scholar
• Tarr J , EggletonP: Immune function of C1q and its modulators CD91 and CD93.Crit. Rev. Immunol.25(4), 305–330 (2005)
   PubMed Web of Science ®Google Scholar
• Lu JH , TheBK, WangLet al. : The classical and regulatory functions of C1q in immunity and autoimmunity.Cell. Mol. Immunol.5(1), 9–21 (2008).
   PubMed Web of Science ®Google Scholar
• Opavsky R , HaviernikP, JurkovicovaDet al. : Molecular characterization of the mouse TEM1/endosialin gene regulated by cell density in vitro and expressed in normal tissues in vivo.J. Biol. Chem.276(42), 38795–38807 (2001).
   PubMed Web of Science ®Google Scholar
• Carson-Walter EB , WatkinsDN, NandaA, VogelsteinB, KinzlerKK, St Croix B: Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res.61, 6649–6655 (2001).
   PubMed Web of Science ®Google Scholar
• Nanda A , KarimB, PengZet al. : Tumor endothelial marker 1 (Tem 1) functions in the growth and progression of abdominal tumors.Proc. Natl Acad. Sci. USA103(9), 3351–3356 (2006).
   PubMed Web of Science ®Google Scholar
• Harris AL : Hypoxia – a key regulatory factor in tumour growth.Nat. Rev. Cancer2, 38–47 (2002).
   PubMed Web of Science ®Google Scholar
• Liao D , JohnsonRS: Hypoxia: a key regulator of angiogenesis in cancer.Cancer Metastasis Rev.26, 281–290 (2007).
   PubMed Web of Science ®Google Scholar
• Ohradanova A , GradinK, BarathovaMet al. : Hypoxia upregulates expression of human endosialin gene via hypoxia-inducible factor 2.Br. J. Cancer99, 1348–1356 (2008).
   PubMed Web of Science ®Google Scholar
• Tomkowicz B , RybinskiK, FoleyBet al. : Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration.Proc. Natl Acad. Sci. USA104(46), 17965–17970 (2007).
   PubMed Web of Science ®Google Scholar
• Becker R , LenterMC, VollkommerTet al. : Tumor stroma marker endosialin (Tem 1) is a binding partner of metastasis-related protein Mac-2 BP/90K.FASEB J.22, 3059–3067 (2008).
   PubMed Web of Science ®Google Scholar
• Iacobelli S , SismondiP, GiaiMet al. : Prognostic value of a novel circulating serum 90K antigen in breast cancer.Br. J. Cancer69, 172–176 (1994).
   PubMed Web of Science ®Google Scholar
• Marchetti A , TinariN, ButtittaFet al. : Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients.Cancer Res.62, 2535–2539 (2002).
   PubMed Web of Science ®Google Scholar
• Kerbel R , FolkmanJ: Clinical translation of angiogenesis inhibitors.Nat. Rev. Cancer2, 727–739 (2002).
   PubMed Web of Science ®Google Scholar
• St. Croix B , RagoC, VelculescuVet al. : Genes expressed in human tumor endothelium.Science289, 1197–1202 (2000).
   PubMed Web of Science ®Google Scholar
• Nanda A , St. Croix B: Tumor endothelial markers: new targets for cancer therapy. Curr. Opin. Oncol.16, 44–49 (2004).
   PubMed Web of Science ®Google Scholar
• Teicher BA : Newer vascular targets: endosialin (review).Int. J. Oncol.30, 305–312 (2007).
   PubMed Web of Science ®Google Scholar
• Brady J , NealJ, SadakarN, GasqueP: Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors.J. Neuropathol. Exp. Neurol.63(12), 1274–1283 (2004).
   PubMed Web of Science ®Google Scholar
• Madden SL , CookBP, NachtMet al. : Vascular gene expression in nonneoplastic and malignant brain.Am. J. Pathol.165(2), 601–608 (2004).
   PubMed Web of Science ®Google Scholar
• Asahara T , MasudaH, TakahashiTet al. : Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.Circ. Res.85, 221–228 (1999).
   PubMed Web of Science ®Google Scholar
• Duda D , CohenK, KozinSet al. : Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors.Blood107, 2774–2776 (2006).
   PubMed Web of Science ®Google Scholar
• Lyden D , HattoriK, DiasSet al. : Impaired recruitment of bone marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth.Nat. Med.7, 1194–1201 (2001).
   PubMed Web of Science ®Google Scholar
• Goa D , NolanDJ, MellickASet al. : Endothelial progenitor cells control the angiogenic switch in lung mouse metastasis.Science319, 195–198 (2008).
   PubMed Web of Science ®Google Scholar
• Shirakawa K , ShibuyaM, HeikeYet al. : Tumor-infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer.Int. J. Cancer99, 344–351 (2002).
   PubMed Web of Science ®Google Scholar
• Bian X , DuL, ShiJet al. : Correlation of bGF, FGFR-1, and VEGF expression with vascularity and malignancy of human astrocytomas.Anal. Quant. Cytol. Histol.22, 267–274, (2000).
   PubMedGoogle Scholar
• Zhang H , VakilV, BraunsteinMet al. : Circulating endothelial progenitor cells in multiple myeloma: implications and significance.Blood105(8), 3286–3294 (2005).
   PubMed Web of Science ®Google Scholar
• Dome B , TimarJ, DobosJet al. : Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer.Cancer Res.66, 7341–7347 (2006).
   PubMed Web of Science ®Google Scholar
• Peters B , DiazL, PolyakKet al. : Contribution of bone marrow-derived endothelial cells to human tumor vasculature.Nat. Med.11, 261–262 (2005).
   PubMed Web of Science ®Google Scholar
• Bagley RG , RouleauC, St. MartinTet al.: Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248.Mol. Cancer Ther.7(8), 2536–2546 (2008).
   PubMed Web of Science ®Google Scholar
• Conejo-Garcia JR , BuckanovichRJ, BenenciaFet al. : Vascular leukocytes contribute to tumor vascularization.Blood105(2), 679–681 (2005).
   PubMed Web of Science ®Google Scholar
• Naik RP , JinD, ChuangEet al. : Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer.Breast Cancer Res. Treat.107(1), 133–138 (2008).
   PubMed Web of Science ®Google Scholar
• Yu D , SunX, QiuYet al. : Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma.Clin. Cancer Res.13(13), 3814–3824 (2007).
   PubMed Web of Science ®Google Scholar
• Bogos K , Renyi-VamosF, DdobosJet al. : High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer.Clin. Cancer Res.15(5), 1741–1746 (2009).
   PubMed Web of Science ®Google Scholar
• Zheng PP , HopWC, LuiderTMet al. : Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas.Ann. Neurol.62, 40–48 (2007).
   PubMed Web of Science ®Google Scholar
• Donate F , JuarexJC, BurnettMEet al. : Identification of biomarkers for the antiangiogenic and antitumour activity of superoxide dismutatase (SOD1) inhibitor tetrathiomolybdate (ATN-224).Br. J. Cancer98(4), 776–783 (2008).
   PubMed Web of Science ®Google Scholar
• Bertolini F , ShakedY, MancusoP, KerbelRS: The multifaceted circulating endothelial cell in cancer: towards marker and target identification.Nat. Rev.6, 835–845 (2006).
   Google Scholar
• Shaked Y , CiarrocchiA, FrancoMet al. : Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.Science313(5794), 1785–1787 (2006).
   PubMed Web of Science ®Google Scholar
• Hirschi KK , D‘AmorePA: Pericytes in the microvasculature.Cardiovasc. Res.32, 687–698 (1996).
   PubMed Web of Science ®Google Scholar
• Allt G , LawrensonJG. Pericytes: cell biology and pathology. Cells Tissues Organs169, 1–11 (2001).
   PubMed Web of Science ®Google Scholar
• Bagley RG , HonmaN, WeberWet al. : Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization.Microvasc. Res.76, 280–288 (2008).
   Web of Science ®Google Scholar
• Simonavicius N , RobertsonD, Bax,DA, JonesC, HuijbersIJ, IsackeCM: Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade gliomas.Mod. Pathol.21(3) 308–315 (2008).
   PubMed Web of Science ®Google Scholar
• MacFadyen J , SavageK, WienkeD, IsackeCM: Endosialin is expressed on stromal fibroblasts and CNS pericytes in mouse embryos and is downregulated during development.Gene Expr. Patterns7, 363–369 (2007).
   PubMed Web of Science ®Google Scholar
• Rupp C , DolznigH, PuriCet al. : Mouse endosialin, a C-type lectin-like surface receptor: expression during embryonic development and induction in experimental cancer neoangiogenesis.Cancer Immun.6, 10–21 (2006).
   PubMedGoogle Scholar
• Christian S , WinklerR, HelfrichIet al. : Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells.Am. J. Pathol.172(2), 486–494 (2008).
   PubMed Web of Science ®Google Scholar
• MacFadyen JR , HaworthO, RobertsonDet al. : Endosialin (TEM 1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium.FEBS Lett.579, 2569–2575 (2005).
   PubMed Web of Science ®Google Scholar
• Rupp C , DolznigH, PuriCet al. : Laser capture microdissection of epithelial cancers guided by antibodies against fibroblast activation protein and endosialin.Diagn. Mol. Pathol.15(1), 35–42 (2006).
   PubMedGoogle Scholar
• Huber MA , KrautN, SchweiferNet al. : Expression of stromal cell markers in distinct compartments of human skin cancers.J. Cutan. Pathol.33, 145–155 (2006).
   PubMed Web of Science ®Google Scholar
• Lax S , HouTZ, JenkinsonEet al. : CD248/endosialin is dynamically expressed on a subset of stromal cells during lymphoid tissue development, splenic remodeling and repair.FEBS Lett.581, 3550–3556 (2007).
   PubMed Web of Science ®Google Scholar
• Dolznig H , SchweiferN, PuriCet al. : Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin.Cancer Immun.5, 10 (2005).
   PubMedGoogle Scholar
• Bagley RG , WeberW, RouleauCet al. : Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers.Int. J. Oncol.34, 619–627 (2009).
   PubMed Web of Science ®Google Scholar
• Karnoub AE , DashAB, VoAPet al. : Mesenchymal stem cells within tumour stroma promote breast cancer metastasis.Nature449, 557–565 (2007).
   PubMed Web of Science ®Google Scholar
• Marty C , Langer-MachovaZ, SigristS, SchottH, SchwendenerRA, Ballmer-HoferK: Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy.Cancer Lett.235, 298–308 (2006).
   PubMed Web of Science ®Google Scholar
• Davies G , RmaliKA, WatkinsG, ManselRE, MasonMD, JiangWG: Elevated levels of tumour endothelial marker-8 in human breast cancer and its clinical significance.Int. J. Oncol.29, 1311–1317 (2006).
   PubMed Web of Science ®Google Scholar
• Rmali KA , PuntisMCA, JiangWG: Prognostic values of tumor endothelial markers in patients with colorectal cancer.World J. Gastroenterol.11(9), 1283–1286 (2005).
   PubMed Web of Science ®Google Scholar
• Rouleau C , CurielM, WeberWet al. : Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma.Clin. Cancer Res.14(22), 7223–7236 (2008).
   PubMed Web of Science ®Google Scholar
• Ishida I , TomizukaK, YoshidaHet al. : Production of human monoclonal and polyclonal antibodies in TransChromo animals.Cloning Stem Cells4(1), 91–102 (2002).
   PubMedGoogle Scholar
• Tomizuka K , ShinoharaT, YoshidaHet al. : Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and k loci and expression of fully human antibodies.Proc. Natl Acad. Sci. USA97(2), 722–727 (2000).
   PubMed Web of Science ®Google Scholar
• Gibbs CP , KukekovVG, ReithJDet al. : Stem-like cells in bone sarcomas: implications for tumorigenesis.Neoplasia7(11), 967–976 (2005).
   PubMed Web of Science ®Google Scholar
• Fujii H , HonokiK, TsujiuchiTet al. : Reduced expression of INK4a/ARF genes in stem-like sphere cells from rat sarcomas.Biochem. Biophys. Res. Commun.362, 773–778 (2007).
   PubMed Web of Science ®Google Scholar
• Fujii H , HonokiK, TsujiuchiT, KidoA, YoshitaniK, TakakuraY. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int. J. Oncol.34(5), 1381–1386 (2009).
   PubMed Web of Science ®Google Scholar
• Kasper B , GilT, D‘HondtV, GebhartM, AwadaA: Novel treatment strategies for soft tissue sarcoma.Crit. Rev. Oncol. Hematol.62, 9–15 (2007).
   PubMed Web of Science ®Google Scholar
• Schuetze SM . Chemotherapy in the management of osteosarcoma and Ewing‘s sarcoma. J. Natl Compr. Canc. Netw.5, 449–455 (2007).
   PubMedGoogle Scholar
• Kasper B , GilT, AwadaA: Chemotherapy in the management of osteosarcoma and Ewing‘s sarcoma: disappointment or challenge?Curr. Opin. Oncol.19, 336–340 (2007).
   PubMed Web of Science ®Google Scholar
• Loges S , RoncalC, CarmelietP: Development of targeted angiogenic medicine.J. Thromb. Haemost.7, 21–33 (2009).
   PubMed Web of Science ®Google Scholar
• Jain RK , DudaDG, SorensenAG: Emerging paradigms and potential biomarkers of response and resistance in antiangiogenic therapy of cancer. In: ASCO Educational Book.716–721 (2009).
   Google Scholar

▪ Website

• Becker R, Augustin HG: CD248. Atlas of genetics and cytogenetics in oncology and haematology (2008). http://AtlasGeneticsOncology.org/Genes/CD248ID968ch11q13.html
   Google Scholar